AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Texas

SB3005

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

Status

Did not pass; died when the session ended

2025 Session

IntroducedMar 14, 2025 (done)
PassedDid not happen (skipped)
SignedDid not happen (skipped)
Law in effectDid not happen (skipped)

Sponsor: Cesar Blanco (Democrat)
Type: Study/Task Force
Substances: Psilocybin

Official text

Summary (from PoliPsy)

Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: capitol.texas.gov

Legislative history

April 29, 2025
Co-author authorized
April 7, 2025
Referred
March 14, 2025
Introduced

Loading bill…